Sutro Biopharma, Inc.
STRO
$0.81
$0.00470.58%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -56.88% | -59.64% | 230.90% | 197.83% | 106.66% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -56.88% | -59.64% | 230.90% | 197.83% | 106.66% |
| Cost of Revenue | -72.55% | -448.22% | -92.65% | -102.54% | -116.64% |
| Gross Profit | -39.19% | -27.24% | 222.56% | 275.12% | 347.75% |
| SG&A Expenses | -18.04% | -22.58% | -7.06% | -4.52% | -0.37% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 14.77% | 23.66% | 26.36% | 27.71% | 24.73% |
| Operating Income | -121.30% | -167.09% | 28.41% | 33.18% | 21.52% |
| Income Before Tax | -149.95% | -154.06% | 36.41% | 24.85% | 23.65% |
| Income Tax Expenses | -86.72% | -87.01% | 563.10% | 3,133.33% | 514.75% |
| Earnings from Continuing Operations | -113.31% | -112.99% | 28.12% | 12.76% | 11.67% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -113.31% | -112.99% | 28.12% | 12.76% | 11.67% |
| EBIT | -121.30% | -167.09% | 28.41% | 33.18% | 21.52% |
| EBITDA | -129.62% | -180.41% | 29.75% | 35.02% | 23.32% |
| EPS Basic | -57.60% | -67.78% | 44.21% | 25.39% | 20.76% |
| Normalized Basic EPS | -57.24% | -104.78% | 40.20% | 35.83% | 21.66% |
| EPS Diluted | -57.60% | -67.78% | 44.21% | 25.39% | 20.76% |
| Normalized Diluted EPS | -57.24% | -104.78% | 40.20% | 35.83% | 21.66% |
| Average Basic Shares Outstanding | 35.14% | 27.68% | 20.67% | 15.65% | 13.13% |
| Average Diluted Shares Outstanding | 35.14% | 27.68% | 20.67% | 15.65% | 13.13% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |